Tianlei Chen
About Tianlei Chen
Tianlei Chen is a Principal Statistician at Bristol-Myers Squibb with extensive experience in hematology and oncology drug development.
Title and Current Role
Tianlei Chen is currently a Principal Statistician at Bristol-Myers Squibb, stationed in Berkeley Heights, New Jersey. In this role, he leverages his extensive experience in both early and late-stage drug development to support the company's clinical trial endeavors. His work includes statistical planning and analysis, which are integral components of the clinical development process.
Professional Experience at Celgene
Tianlei Chen has held multiple roles at Celgene, reflecting his professional growth in the field of statistics. He served as a Principal Statistician for one month in 2019, a Sr Statistician for two years from 2017 to 2019, and a Statistician for two years from 2015 to 2017 in Berkeley Heights, New Jersey. During his tenure, Chen supported the submission of an immunology drug during its late development phase and contributed significantly to Phase 3b oncology studies.
Internship at Novartis
In 2014, Tianlei Chen worked as a Summer Intern in Biometrics and Data Management at Novartis in Cambridge, MA. This role provided him with early exposure to the field of biostatistics, laying the groundwork for his future contributions to clinical trials and drug development.
Educational Background
Tianlei Chen completed his Doctor of Philosophy (PhD) in Statistics at Virginia Tech. His advanced education equipped him with the theoretical knowledge and practical skills necessary for his various roles in the pharmaceutical industry. This academic background has been fundamental in his work on statistical planning and analysis for clinical trials.
Experience in Hematology and Oncology Drug Development
Tianlei Chen has a strong background in hematology and oncology, with demonstrated expertise in both early and late-stage drug development. He has worked on Phase 1 studies in these areas and played a key role in the strategic planning and execution of clinical trials. His contributions span across both statistical analysis and medical affairs, highlighting his comprehensive understanding of the drug development lifecycle.